IRON Disc Medicine Inc
Price Chart
Executive Summary
Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked protoporphyria (XLP) patients in the U.S., while noting that Phase 3 APOLLO topline data is expected in Q4 2026, with a CRL response and FDA decision expected by mid-2027. This is a procedural step that does not change the binary risk/reward of the upcoming Phase 3 readout and regulatory decision, and does not add new safety/efficacy data.
Actionable Insight
The EAP launch is a modest positive for patient access optics but does not derisk APOLLO. Key binary catalyst is APOLLO topline data in Q4 2026; the mid-2027 FDA decision timeline reinforces that near-term stock movement will be driven by Phase 3 results, not today's announcement. Traders should focus on APOLLO enrollment and data timing updates.
Key Facts
- EAP launched for bitopertin in eligible EPP/XLP patients aged 12+ in the U.S.
- Phase 3 APOLLO double-blind, placebo-controlled trial ongoing; topline data expected Q4 2026
- Disc Medicine expects to submit a CRL response with FDA decision by mid-2027
- Bitopertin is not approved in any jurisdiction; an earlier CRL prompted the updated timeline
- Company market cap ~$2.7B; analyst consensus is heavily bullish (95% buy-side)
Financial Impact
No financial data provided in this press release; the EAP is a non-revenue-generating program
Risk Factors
- Phase 3 APOLLO may fail to meet primary endpoint, as bitopertin previously received a CRL
- CRL response may be rejected by FDA, delaying or preventing approval beyond mid-2027
- EAP access does not guarantee favorable regulatory outcome or commercial adoption
- High cash burn for clinical-stage biotech with no approved products
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304352 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Press Release
| $68.51 awaiting T+5 | awaiting T+5 | — | $67.99 (−0.76%) |
|
Jun 9, 2026
3d ago
|
Press Release
| $67.50 awaiting T+5 | awaiting T+5 | — | $67.99 (+0.73%) |
|
Jun 1, 2026
11d ago
|
Press Release
| $71.97 $67.00 | ▼ −6.91% | ▼ −4.16% | $67.99 (−5.53%) |
|
May 5, 2026
5w ago
|
8-K
| $67.59 $69.23 | ▲ +2.43% | ▲ +0.44% | $67.99 (+0.59%) |
|
May 5, 2026
5w ago
|
Press Release
| $67.59 $69.23 | ▲ +2.43% | ▲ +0.44% | $67.99 (+0.59%) |
|
Apr 13, 2026
8w ago
|
Insider Cluster
| $68.46 $71.41 | ▼ −4.31% | ▼ −1.01% | $67.99 (+0.69%) |
|
Feb 26, 2026
15w ago
|
8-K
| $67.91 $60.34 | ▲ +11.15% | ▲ +10.02% | $67.99 (−0.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access